PDCD1 and neoplasm: Sunitinib treatment decreases MDSC and Treg numbers in the tumor tissue and regulates the expression of negative co-stimulatory molecules such as CTLA-4 and PD-1 in both CD4 and CD8 T cells as well as PD-L1 expression on MDSC and plasmacytoid dendritic cells [42].